A study in Biochemical Genetics reported that adding the DNA methyltransferase inhibitor decitabine to a modified chemotherapy regimen enhanced responses in patients with high‑risk karyotype acute myeloid leukemia (AML). Researchers led by Liu, Lu, and Sun showed improved molecular and clinical endpoints compared with historical controls. The trial focused on a subset of AML patients with adverse cytogenetics who traditionally derive limited benefit from standard induction. Decitabine’s epigenetic activity appears to sensitize leukemic blasts to cytotoxic agents in this population. If validated in larger randomized trials, the regimen could become a tailored approach for a high‑risk AML cohort that lacks effective first‑line options.